Oncternal Therapeutics (ONCT) Competitors

GT Biopharma (NASDAQ:GTBP) and Oncternal Therapeutics (NASDAQ:ONCT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, community ranking, dividends, media sentiment, risk, valuation and institutional ownership.

Do analysts recommend GTBP or ONCT?

GT Biopharma presently has a consensus price target of $11.00, suggesting a potential upside of 364.14%. Oncternal Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 1,798.97%. Given Oncternal Therapeutics' higher possible upside, analysts clearly believe Oncternal Therapeutics is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GT Biopharma	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50
Oncternal Therapeutics	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25

Is GTBP or ONCT more profitable?

GT Biopharma has a net margin of 0.00% compared to Oncternal Therapeutics' net margin of -1,599.95%. Oncternal Therapeutics' return on equity of -177.58% beat GT Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GT Biopharma	N/A	-257.47%	-131.09%
Oncternal Therapeutics	-1,599.95%	-177.58%	-131.30%

Which has more risk and volatility, GTBP or ONCT?

GT Biopharma has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500. Comparatively, Oncternal Therapeutics has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500.

Which has higher valuation and earnings, GTBP or ONCT?

GT Biopharma has higher earnings, but lower revenue than Oncternal Therapeutics. GT Biopharma is trading at a lower price-to-earnings ratio than Oncternal Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GT Biopharma	N/A	N/A	-$7.60M	-$7.00	-0.34
Oncternal Therapeutics	$790K	1.97	-$39.48M	-$11.69	-0.05

Does the media favor GTBP or ONCT?

In the previous week, GT Biopharma had 1 more articles in the media than Oncternal Therapeutics. MarketBeat recorded 2 mentions for GT Biopharma and 1 mentions for Oncternal Therapeutics. GT Biopharma's average media sentiment score of 0.89 beat Oncternal Therapeutics' score of 0.00 indicating that GT Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GT Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Oncternal Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community believe in GTBP or ONCT?

GT Biopharma received 85 more outperform votes than Oncternal Therapeutics when rated by MarketBeat users. Likewise, 63.24% of users gave GT Biopharma an outperform vote while only 23.36% of users gave Oncternal Therapeutics an outperform vote.

Company	Underperform	Outperform
GT Biopharma	Outperform Votes 117 63.24%	Underperform Votes 68 36.76%
Oncternal Therapeutics	Outperform Votes 32 23.36%	Underperform Votes 105 76.64%

Do institutionals & insiders believe in GTBP or ONCT?

8.1% of GT Biopharma shares are held by institutional investors. Comparatively, 16.0% of Oncternal Therapeutics shares are held by institutional investors. 10.9% of GT Biopharma shares are held by company insiders. Comparatively, 11.2% of Oncternal Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

GT Biopharma beats Oncternal Therapeutics on 10 of the 17 factors compared between the two stocks.